| DC12081 |
LY2828360
Featured
|
LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling. |
|
| DC8643 |
LY2835219 free base (Abemaciclib)
Featured
|
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
|
| DC5062 |
LY2835219(Abemaciclib)
Featured
|
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
|
| DC7019 |
LY-2874455
Featured
|
LY2874455 is a novel and potent FGF/FGFR inhibitor. |
|
| DC5053 |
LY2886721
Featured
|
LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease. |
|
| DC1058 |
LY294002
Featured
|
LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively. |
|
| DC22312 |
LY2940094
Featured
|
LY2940094 is a potent and selective nociceptin receptor antagonist which inhibits excessive feeding behavior in rodents. |
|
| DC7191 |
LY-2940680(Taladegib)
Featured
|
LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. |
|
| DC10833 |
LY2955303
Featured
|
LY2955303 is a potent and selective RAR-gamma antagonist for the treatment of osteoarthritis pain. |
|
| DC23688 |
LY-3000328
Featured
|
LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively. |
|
| DC8344 |
LY3009120
Featured
|
LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
|
| DC10219 |
LY3023414
Featured
|
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
|
| DC7210 |
LY-303511(Nv-128)
Featured
|
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. |
|
| DC7884 |
LY310762
Featured
|
LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor. |
|
| DC21259 |
LY 3130481
Featured
|
LY3130481 (CERC611) is a potent, selective, noncompetitive TARP γ8-associated AMPA receptors with IC50 of 65.3 nM (GluA1/TARP γ-8), with no activity for γ-2 (cerebellum) or other TARP members. |
|
| DC20262 |
LY3154207
Featured
|
LY3154207 is a potent and selective dopamine receptor D1 positive allosteric modulator for the treatment of Parkinson's disease dementia. |
|
| DC7526 |
Varespladib
Featured
|
LY315920 (Varespladib) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM,. Phase 3. |
|
| DC9766 |
LY3177833
Featured
|
LY3177833 is a novel CDC7 inhibitor,CDC7/DBF4 IC50 = 3.3 nM, pMCM2 (S53) IC50 = 290 nM and IVTI TEC70 = 1.6 mcM. |
|
| DC10675 |
LY3200882
Featured
|
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
|
| DC11330 |
LY320135
Featured
|
LY320135 is a selective cannabinoid (CB) receptor 1 antagonist (Kis = 224 and >10,000 nM for CB1 and CB2, respectively, in vitro). |
|
| DC21253 |
N-(3-((4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide
Featured
|
LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease.. |
|
| DC10640 |
LY3214996
Featured
|
LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
|
| DC8523 |
LY333531 Hydrochloride(Ruboxistaurin HCl)
Featured
|
LY-333,531 Hydrochloride is a potent, selective inhibitor of Protein Kinase C isozymes, PKC beta I (IC50 = 4.7 nM) and PKC beta II (IC50 = 5.9 nM). It is potentially beneficial for cancer research. |
|
| DC10712 |
LY334370
Featured
|
LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM. |
|
| DC2018 |
LY335979 (Zosuquidar 3HCl)
Featured
|
LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. |
|
| DC22784 |
LY-345899
Featured
|
LY-345899 (LY345899) is a novel potent, cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with IC50 of 96 nM and 663 nM, respectively; MTHFD2 is a novel target for drug development. |
|
| DC6305 |
LY364947
Featured
|
LY364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, shows 7-fold selectivity over TGFβR-II. |
|
| DC7192 |
LY-404039
Featured
|
LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor. |
|
| DC5036 |
LY-411575
Featured
|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM. |
|
| DC22435 |
LY487379
Featured
|
LY-487379 is a potent, selective positive allosteric modulator of mGluR2 (EC50=0.27 uM) without activity at mGluR3; shows no intrinsic agonist or antagonist activity at hmGluR2, markedly potentiates glutamate-stimulated [35S]GTPgammaS binding at hmGluR2; potentiates synaptically evoked mGluR2 responses in rat hippocampal slices, modulates excitatory synaptic transmission in the rat globus pallidus. |
|
